$4.00 was ridiculous. I still think it's way overvalued at $3.50, but for some unknown reason the Nexavar news isn't sinking in. PI-88 is in big, big trouble trying to compete with a Onyx's best-in-class treatment.
A share price of $2 seems a more realistic valuation.
